Transforming growth factor beta

Transforming growth factor beta (TGF-β) is a multifunctional cytokine belonging to the transforming growth factor superfamily that includes three^[1] different mammalian isoforms (TGF-β 1 to 3, HGNC symbols TGFB1, TGFB2, TGFB3) and many other signaling proteins. TGFB proteins are produced by all white blood cell lineages.

Computer graphic of TGF-beta. TGF-beta is a cytokine with three different isoforms, which regulates many cellular functions including cell proliferation, differentiation, adhesion and migration

Activated TGF-β complexes with other factors to form a serine/threonine kinase complex that binds to TGF-β receptors. TGF-β receptors are composed of both type 1 and type 2 receptor subunits. After the binding of TGF-β, the type 2 receptor kinase phosphorylates and activates the type 1 receptor kinase that activates a signaling cascade.^[2] This leads to the activation of different downstream substrates and regulatory proteins, inducing transcription of different target genes that function in differentiation, chemotaxis, proliferation, and activation of many immune cells.^[2][3]

TGF-β is secreted by many cell types, including macrophages, in a latent form in which it is complexed with two other polypeptides, latent TGF-beta binding protein (LTBP) and latency-associated peptide (LAP). Serum proteinases such as plasmin catalyze the release of active TGF-β from the complex. This often occurs on the surface of macrophages where the latent TGF-β complex is bound to CD36 via its ligand, thrombospondin-1 (TSP-1). Inflammatory stimuli that activate macrophages enhance the release of active TGF-β by promoting the activation of plasmin. Macrophages can also endocytose IgG-bound latent TGF-β complexes that are secreted by plasma cells and then release active TGF-β into the extracellular fluid.^[4] Among its key functions is regulation of inflammatory processes, particularly in the gut.^[5] TGF-β also plays a crucial role in stem cell differentiation as well as T-cell regulation and differentiation.^[6][7]

Because of its role in immune and stem cell regulation and differentiation, it is a highly researched cytokine in the fields of cancer, auto-immune diseases, and infectious disease.

The TGF-β superfamily includes endogenous growth inhibiting proteins; an increase in expression of TGF-β often correlates with the malignancy of many cancers and a defect in the cellular growth inhibition response to TGF-β. Its immunosuppressive functions then come to dominate, contributing to oncogenesis.^[8] The dysregulation of its immunosuppressive functions is also implicated in the pathogenesis of autoimmune diseases, although their effect is mediated by the environment of other cytokines present.^[5][9]

Structure

The primary 3 mammalian types are:

• TGF beta 1 – TGFB1^[10][11]
• TGF beta 2 – TGFB2^[12][13]
• TGF beta 3 – TGFB3^[14][15]

A fourth member of the subfamily, TGFB4, has been identified in birds and a fifth, TGFB5, only in frogs.^[16]

The peptide structures of the TGF-β isoforms are highly similar (homologies on the order of 70–80%). They are all encoded as large protein precursors; TGF-β1 contains 390 amino acids and TGF-β2 and TGF-β3 each contain 412 amino acids. They each have an N-terminal signal peptide of 20–30 amino acids that they require for secretion from a cell, a pro-region called latency-associated peptide (LAP - Alias: Pro-TGF beta 1, LAP/TGF beta 1), and a 112-114 amino acid C-terminal region that becomes the mature TGF-β molecule following its release from the pro-region by proteolytic cleavage.^[17] The mature TGF-β protein dimerizes to produce a 25 KDa active protein with many conserved structural motifs.^[18] TGF-β has nine cysteine residues that are conserved among its family. Eight form disulfide bonds within the protein to create a cysteine knot structure characteristic of the TGF-β superfamily. The ninth cysteine forms a disulfide bond with the ninth cysteine of another TGF-β protein to produce a dimer.^[19] Many other conserved residues in TGF-β are thought to form secondary structure through hydrophobic interactions. The region between the fifth and sixth conserved cysteines houses the most divergent area of TGF-β proteins that is exposed at the surface of the protein and is implicated in receptor binding and specificity of TGF-β.

Latent TGF-β complex

All three TGF-βs are synthesized as precursor molecules containing a propeptide region in addition to the TGF-β homodimer.^[20] After it is synthesized, the TGF-β homodimer interacts with a Latency-Associated Peptide (LAP), a protein derived from the N-terminal region of the TGF-β gene product, forming a complex called Small Latent Complex (SLC). This complex remains in the cell until it is bound by another protein called Latent TGF-β-Binding Protein (LTBP), forming a larger complex called Large Latent Complex (LLC). It is this LLC that gets secreted to the extracellular matrix (ECM).^[21]

In most cases, before the LLC is secreted, the TGF-β precursor is cleaved from the propeptide but remains attached to it by noncovalent bonds.^[22] After its secretion, it remains in the extracellular matrix as an in activated complex containing both the LTBP and the LAP which need to be further processed in order to release active TGF-β.^[23] The attachment of TGF-β to the LTBP is by disulfide bond which allows it to remain inactive by preventing it from binding to its receptors ^{[citation needed]}. Because different cellular mechanisms require distinct levels of TGF-β signaling, the inactive complex of this cytokine gives opportunity for a proper mediation of TGF-β signaling.^[23]

There are four different LTBP isoforms known, LTBP-1, LTBP-2, LTBP-3 and LTBP-4.^[24] Mutation or alteration of LAP or LTBP can result in improper TGF-β signaling. Mice lacking LTBP-3 or LTBP-4 demonstrate phenotypes consistent to phenotypes seen in mice with altered TGF-β signaling.^[25] Furthermore, specific LTBP isoforms have a propensity to associate with specific LAP•TGF-β isoforms. For example, LTBP-4 is reported to bind only to TGF-β1,^[26] thus, mutation in LTBP-4 can lead to TGF-β associated complications which are specific to tissues that predominantly involves TGF-β1. Moreover, the structural differences within the LAP's provide different latent TGF-β complexes which are selective but to specific stimuli generated by specific activators.

Activation

Although TGF-β is important in regulating crucial cellular activities, only a few TGF-β activating pathways are currently known, and the full mechanism behind the suggested activation pathways is not yet well understood. Some of the known activating pathways are cell or tissue specific, while some are seen in multiple cell types and tissues.^[23][27] Proteases, integrins, pH, and reactive oxygen species are just few of the currently known factors that can activate TGF-β, as discussed below.^[28][29][30] It is well known that perturbations of these activating factors can lead to unregulated TGF-β signaling levels that may cause several complications including inflammation, autoimmune disorders, fibrosis, cancer and cataracts.^[31][32] In most cases, an activated TGF-β ligand will initiate the TGF-β signaling cascade as long as TGF-β receptors I and II are available for binding. This is due to a high affinity between TGF-β and its receptors, suggesting why the TGF-β signaling recruits a latency system to mediate its signaling.^[23]

Integrin-independent activation

Activation by protease and metalloprotease

Plasmin and a number of matrix metalloproteinases (MMP) play a key role in promoting tumor invasion and tissue remodeling by inducing proteolysis of several ECM components.^[28] The TGF-β activation process involves the release of the LLC from the matrix, followed by further proteolysis of the LAP to release TGF-β to its receptors. MMP-9 and MMP-2 are known to cleave latent TGF-β.^[31] The LAP complex contains a protease-sensitive hinge region which can be the potential target for this liberation of TGF-β.^[32] Despite the fact that MMPs have been proven to play a key role in activating TGF-β, mice with mutations in MMP-9 and MMP-2 genes can still activate TGF-β and do not show any TGF-β deficiency phenotypes, this may reflect redundancy among the activating enzymes^[23] suggesting that other unknown proteases might be involved.

Activation by pH

Acidic conditions can denature the LAP. Treatment of the medium with extremes of pH (1.5 or 12) resulted in significant activation of TGF-β as shown by radio-receptor assays, while mild acid treatment (pH 4.5) yielded only 20-30% of the activation achieved by pH 1.5.^[33]

Activation by reactive oxygen species (ROS)

The structure of LAP is important in maintaining its function. Structure modification of LAP can lead to disturb the interaction between LAP and TGF-β and thus activating it. Factors that may cause such modification may include hydroxyl radicals from reactive oxygen species (ROS). TGF-β was rapidly activated after in vivo radiation exposure ROS.^[29]

Activation by thrombospondin-1

Thrombospondin-1 (TSP-1) is a matricellular glycoprotein found in plasma of healthy patients with levels in the range of 50–250 ng/ml.^[34] TSP-1 levels are known to increase in response to injury and during development.^[35] TSP-1 activates latent TGF-beta^[36] by forming direct interactions with the latent TGF-β complex and induces a conformational rearrangement preventing it from binding to the matured TGF-β.^[37]

Activation by Alpha(V) containing integrins

The general theme of integrins participating in latent TGF-β1 activation arose from studies that examined mutations/knockouts of β6 integrin,^[38] αV integrin,^[39] β8 integrin and in LAP. These mutations produced phenotypes that were similar to phenotypes seen in TGF-β1 knockout mice.^[40] Currently there are two proposed models of how αV containing integrins can activate latent TGF-β1; the first proposed model is by inducing conformational change to the latent TGF-β1 complex and hence releasing the active TGF-β1 and the second model is by a protease-dependent mechanism.^[30]

Conformation change mechanism pathway (without proteolysis)

αVβ6 integrin was the first integrin to be identified as TGF-β1 activator.^[23] LAPs contain an RGD motif which is recognized by vast majority of αV containing integrins,^[41] and αVβ6 integrin can activate TGF-β1 by binding to the RGD motif present in LAP-β1 and LAP-β3.^[42] Upon binding, it induces adhesion-mediated cell forces that are translated into biochemical signals which can lead to liberation/activation of TGFb from its latent complex.^[43] This pathway has been demonstrated for activation of TGF-β in epithelial cells and does not associate MMPs.^[44]

Integrin protease-dependent activation mechanism

Because MMP-2 and MMP-9 can activate TGF-β through proteolytic degradation of the latent TGF beta complex,^[31] αV containing integrins activate TGF-β1 by creating a close connection between the latent TGF-β complex and MMPs. Integrins αVβ6 and αVβ3 are suggested to simultaneously bind the latent TGF-β1 complex and proteinases, simultaneous inducing conformational changes of the LAP and sequestering proteases to close proximity. Regardless of involving MMPs, this mechanism still necessitate the association of integrins and that makes it a non proteolytic pathway.^[30][45]

Signaling pathways

The SMAD Pathway

The DAXX Pathway

Canonical signaling: The SMAD pathway

Smads are a class of intracellular signalling proteins and transcription factors for the TGF-β family of signalling molecules. This pathway conceptually resembles the Jak-STAT signal transduction pathway characterized in the activation of cytokine receptors implicated, for example, in the B cell isotype switching pathway. As previously stated, the binding of the TGF-β ligand to the TGF-β receptor, the type 2 receptor kinase phosphorylates and activates the type 1 receptor kinase that activates a signaling cascade. In the case of Smad, receptor-activated Smads are phosphorylated by the type 1 TGF-β receptor kinase, and these go on to complex with other Smads, which is able to translocate into the cell nucleus to induce transcription of different effectors.^[46]

More specifically, activated TGF-β complexes bind to the type 2 domain of the TGF-β receptor which then recruits and phosphorylates a type 1 receptor. The type 1 receptor then recruits and phosphorylates a receptor regulated SMAD (R-SMAD). The R-SMAD then binds to the common SMAD (coSMAD) SMAD4 and forms a heterodimeric complex. This complex then enters the cell nucleus where it acts as a transcription factor for various genes, including those to activate the mitogen-activated protein kinase 8 pathway, which triggers apoptosis. The SMAD pathway is regulated by feedback inhibition. SMAD6 and SMAD7 may block type I receptors.^[47] There is also substantial evidence that TGF-β-dependent signaling via the SMAD-3 pathway is responsible for many of the inhibitory functions of TGF-β discussed in later sections and thus it is implicated in oncogenesis.^[48]

The Smads are not the only TGF-β-regulated signaling pathways. Non-Smad signaling proteins can initiate parallel signaling that eventually cooperate with the Smads or crosstalk with other major signaling pathways. Among them, the mitogen-activated protein kinase (MAPK) family that include the extracellular-regulated kinases (ERK1 and 2), Jun N-terminal kinases (JNKs) and p38 MAPK play an important role in the TGF-β signaling.^[49] ERK 1 and 2 are activated via the Raf-Ras-MEK1/2 pathway induced by mitogenic stimuli such as epidermal growth factor,^[50] whereas the JNK and p38 MAPK are activated by the MAPK kinase, activated themselves by the TGF-β-activated kinase-1 (TAK1) upon stress stimuli.^[51]

Apoptosis via the DAXX pathway

TGF-β induces apoptosis, or programmed cell death, in human lymphocytes and hepatocytes. The importance of this function is clear in TGF-β deficient mice which experience hyperproliferation and unregulated autoimmunity.^[43] In a separate apoptotic pathway from the association of death-associated protein 6 (DAXX) with the death receptor Fas, there is evidence of association and binding between DAXX and type 2 TGF-β receptor kinase, wherein DAXX binds to the C-terminal region of the type 2 TGF-β receptor.^[52] The exact molecular mechanism is unknown, but as a general overview, DAXX is then phosphorylated by homeodomain-interacting protein kinase 2 (HIPK2), which then activates apoptosis signal-inducing kinase 1 (ASK1), which goes on to activate the Jun amino-terminal kinase (JNK) pathway and thus apoptosis as seen in the left panel of the adjacent image.^[53][54]

TGFβ receptor inhibitors

Galunisertib is the selective and potent TGFβRI kinase inhibitor.^[55]

TGF-β mimic

The parasitic roundworm Heligmosomoides polygyrus secretes a molecule that mimics the ability of mammalian TGF-β to bind to the TGFβR complex and trigger downstream signalling pathways.^[56] This molecule, termed Hp-TGM, shares no sequence homology to TGF-β and is secreted by H. polygyrus in a biologically active form. Hp-TGM consists of 5 domains, with the first three shown to crucial for interaction with the TGFβR complex, with functions for domains 4 and 5 not yet known.^[57][58] Importantly, Hp-TGM shows promise as a novel therapeutic as it induces less fibrosis than TGF-β in vivo in mice and can be used to induce populations of human FOXP3⁺ regulatory T cells that had much greater stability than those induced by TGF-β.^[59]

Effects on immune cells

T lymphocytes

TGF-β1 plays a role in the induction from CD4⁺ T cells of both induced T_reg cells (iT_reg cells), which have a regulatory function, and T_h17 cells, which secrete pro-inflammatory cytokines.^[60][61]

TGF-β1 alone precipitates the expression of FOXP3 and T_reg differentiation from activated T helper cells, and the mechanism for this differentiation is unknown for both induced T regulatory cells as well as natural T regulatory cells. In mouse models, the effect of TGF-β1 appears to be age-dependent.^[62]

Studies show that neutralization of TGF-β1 in vitro inhibits the differentiation of helper T cells into T_h17 cells. The role of TGF-β1 in the generation of T_h17 cells goes against its dominant conceptualization as an anti-inflammatory cytokine; however, the shared requirement between inflammatory and anti-inflammatory immune cells suggests that an imbalance between these two cell types can be an important link to autoimmunity.^[60] Co-activation by IL-6 from activated dendritic cells, which serves to activate the transcription factor STAT3, is required in addition to TGF-β1 for the differentiation of T_h17 cells. However, the molecular mechanism of T_h17 differentiation is not well understood.^[62] Because T_h17 cells are distinct from T_h1 and T_h2 lineages in that they have been shown to be capable of regulatory functions, this is further evidence of TGF-β1's regulatory function in the immune system.^[63]

B lymphocytes

TGF-β has mainly inhibitory effects on B lymphocytes. TGF-β inhibits B cell proliferation. The exact mechanism is unknown, but there is evidence that TGF-β inhibits B cell proliferation by inducing the transcription factor Id3, inducing expression of cyclin-dependent kinase inhibitor 21 (a regulator of cell cycle progression through the G1 and S phase), and repressing other key regulatory genes such as c-myc and ATM.^[64][65] CD40, a key surface molecule in the activation of the innate immune response, can induce Smad7 expression to reverse the growth inhibition of B cells induced by TGF-β.^[66] TGF-β also blocks B cell activation and promotes class switching IgA in both human and mouse B cells and has an otherwise inhibitory function for antibody production.^[64]

TGF-β also induces apoptosis of immature or resting B cells; the mechanism is unknown, but may overlap with its anti-proliferation pathway. TGF-β has been shown to downregulate c-myc as it does in the inhibition of B cell proliferation. It is also known to induce NF-κB inhibitor IKBa, inhibiting NF-κB activation.^[67] NF-κB is a transcription factor that regulates the production of cytokines like IL-1, TNF-a, and defensins, although its function in apoptosis may be separate from this function.

Macrophages

The general consensus in the literature is that TGF-β stimulates resting monocytes and inhibits activated macrophages. For monocytes, TGF-β has been shown to function as a chemoattractant as well as an upregulator of anti-inflammatory response.^[68] However, TGF-β has also been shown to downregulate inflammatory cytokine production in monocytes and macrophages, likely by the aforementioned inhibition of NF-κB.^[69] This contradiction may be due to the fact that the effect of TGF-β has been shown to be highly context-dependent.^[70]

TGF-β is thought to play a role in alternative macrophage activation seen in lean mice, and these macrophages maintain an anti-inflammatory phenotype. This phenotype is lost in obese mice, who have not only more macrophages than lean mice but also classically activated macrophages which release TNF-α and other pro-inflammatory cytokines that contribute to a chronically pro-inflammatory milieu.^[71]

Cell cycle

TGF-β plays a crucial role in the regulation of the cell cycle by blocking progress through G₁ phase. TGF-β causes synthesis of p15 and p21 proteins, which block the cyclin:CDK complex responsible for retinoblastoma protein (Rb) phosphorylation. Thus, TGF-β blocks advancement through the G₁ phase of the cycle.^[72] In doing so, TGF-β suppresses expression of c-myc, a gene which is involved in G₁ cell cycle progression.^[72]

Clinical significance

Cancer

In normal cells, TGF-β, acting through its signaling pathway, stops the cell cycle at the G1 stage to stop proliferation, induce differentiation, or promote apoptosis. In many cancer cells, parts of the TGF-β signaling pathway are mutated, and TGF-β no longer controls the cell. These cancer cells proliferate. The surrounding stromal cells (fibroblasts) also proliferate. Both cells increase their production of TGF-β. This TGF-β acts on the surrounding stromal cells, immune cells, endothelial and smooth-muscle cells. It causes immunosuppression and angiogenesis, which makes the cancer more invasive.^[73] TGF-β1 has been implicated in the process of activating Hepatic Stellate Cells (HSCs) with the magnitude of hepatic fibrosis being in proportion to increase in TGF-β levels. Studies have shown that ACTA2 is associated with TGF-β pathway that enhances contractile properties of HSCs leading to Liver fibrosis.^[74] TGF-β also converts effector T-cells, which normally attack cancer with an inflammatory (immune) reaction, into regulatory (suppressor) T-cells, which turn off the inflammatory reaction. Normal tissue integrity is preserved by feedback interactions between different cell types that express adhesion molecules and secrete cytokines. Disruption of these feedback mechanisms in cancer damages a tissue. When TGF-β signaling fails to control NF-κB activity in cancer cells, this has at least two potential effects: first, it enables the malignant tumor to persist in the presence of activated immune cells, and second, the cancer cell outlasts immune cells because it survives in the presence of apoptotic, and anti-inflammatory mediators.^[75]

Furthermore, forkhead box protein 3 (FOXP3) as a transcription factor is an essential molecular marker of regulatory T (T_reg) cells. FOXP3 polymorphism (rs3761548) might be involved in cancer progression like gastric cancer through influencing Tregs function and the secretion of immunomodulatory cytokines such as IL-10, IL-35, and TGF-β.^[76]

Tuberculosis

Mycobacterium tuberculosis infection, or tuberculosis, has been shown to result in increased levels of active TGF-β within the lung.^[77][78] Due to the broad range of suppressive effects of TGF-β on immune cells, computer modeling has predicted that TGF-β blockade may improve immune responses and infection outcome.^[79] Research in animal models has further shown that TGF-β impairs immune responses and elimination of TGF-β signaling results in and enhanced T cell response and lower bacterial burdens.^[80][81][82] Thus, therapies which block TGF-β may have the potential to improve therapy for tuberculosis.

Heart disease

One animal study suggests that cholesterol suppresses the responsiveness of cardiovascular cells to TGF-β and its protective qualities, thus allowing atherosclerosis and heart disease to develop, while statins, drugs that lower cholesterol levels, may enhance the responsiveness of cardiovascular cells to the protective actions of TGF-β.^[83]

TGF-β is involved in regeneration of zebrafish heart.

Marfan syndrome

TGF-β signaling also likely plays a major role in the pathogenesis of Marfan syndrome,^[84] a disease characterized by disproportionate height, arachnodactyly, ectopia lentis and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers, it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice.^[85] This suggests that while the symptoms of Marfan syndrome may seem consistent with a connective tissue disorder, the mechanism is more likely related to reduced sequestration of TGF-β by fibrillin.^[86]

Loeys–Dietz syndrome

TGF-β signaling is also disturbed in Loeys–Dietz syndrome which is caused by mutations in the TGF-β receptor.

Obesity and diabetes

TGF-β/SMAD3 signaling pathway is important in regulating glucose and energy homeostasis and might play a role in diabetic nephropathy.

As noted above in the section about macrophages, loss of TGF-β signaling in obesity is one contributor to the inflammatory milieu generated in the case of obesity.^[71]

Multiple Sclerosis

Induced T regulatory cells (iTreg), stimulated by TGF-β in the presence of IL-2, suppressed the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) via a FOXP3 and IL-10 mediated response. This suggests a possible role for TGF-β and iTreg in the regulation and treatment of MS.^[87]

Decreased levels of TGF-β have been observed in patients diagnosed with multiple sclerosis.^[88] Its role in multiple sclerosis can be explained due to TGF-β role in regulating apoptosis of T_h17 cells.^[88] When TGF-β levels decrease, they are unable to induce T_h17 cells apoptosis.^[88] T_h17 cells secretes TNF-α, which induces demyelination of the oligodendroglial via TNF receptor 1.^[89] The decreased TGF-β levels lead to increased T_h17 cells and subsequently increased TNFα levels.^[88] As a result, demyelination of neurons occurs.^[88] TGF-β have also been observed to induce oligodendrocyte (myelin sheath producing cells) growth.^[88] Hence, the decreased TGF-β levels during MS may also prevent remyelination of neurons.^[88]

Neurological

Higher concentrations of TGF-β are found in the blood and cerebrospinal fluid of patients with Alzheimer's disease as compared to control subjects,^[90] suggesting a possible role in the neurodegenerative cascade leading to Alzheimer's disease symptoms and pathology. The role of TGF-β in neuronal dysfunction remains an active area of research.^[91][92]

Other

Overactive TGF-β pathway, with an increase of TGF-β2,^[93] was reported in the studies of patients with keratoconus.^[94]

There is substantial evidence in animal and some human studies that TGF-β in breast milk may be a key immunoregulatory factor in the development of infant immune response, moderating the risk of atopic disease or autoimmunity.^[95]

Skin aging is caused in part by TGF-β, which reduces the subcutaneous fat that gives skin a pleasant appearance and texture. TGF-β does this by blocking the conversion of dermal fibroblasts into fat cells; with fewer fat cells underneath to provide support, the skin becomes saggy and wrinkled. Subcutaneous fat also produces cathelicidin, which is a peptide that fights bacterial infections.^[96][97]

See also

• Anita Roberts, a molecular biologist who made pioneering observations of TGF-β
• Ziad Mallat, identified a major atheroprotective role of regulatory T cells and associated anti-inflammatory cytokines, IL-10 and TGF-β

References

1. Meng, Xiao-ming; Nikolic-Paterson, David J.; Lan, Hui Yao (June 2016). "TGF-β: the master regulator of fibrosis". Nature Reviews Nephrology. 12 (6): 325–338. doi:10.1038/nrneph.2016.48. PMID 27108839. S2CID 25871413.
2. Massagué J (October 2012). "TGFβ signalling in context". Nature Reviews. Molecular Cell Biology. 13 (10): 616–30. doi:10.1038/nrm3434. PMC 4027049. PMID 22992590.
3. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, et al. (October 1997). "Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling". Nature. 389 (6651): 631–5. Bibcode:1997Natur.389..631N. doi:10.1038/39369. PMID 9335507. S2CID 4311145.
4. AfCS signaling gateway – data center – ligand description
5. Letterio JJ, Roberts AB (April 1998). "Regulation of immune responses by TGF-beta". Annual Review of Immunology. 16 (1): 137–61. doi:10.1146/annurev.immunol.16.1.137. PMID 9597127.
6. Massagué J, Xi Q (July 2012). "TGF-β control of stem cell differentiation genes". FEBS Letters. 586 (14): 1953–8. doi:10.1016/j.febslet.2012.03.023. PMC 3466472. PMID 22710171.
7. Li MO, Flavell RA (August 2008). "TGF-beta: a master of all T cell trades". Cell. 134 (3): 392–404. doi:10.1016/j.cell.2008.07.025. PMC 3677783. PMID 18692464.
8. Massagué J, Blain SW, Lo RS (October 2000). "TGFbeta signaling in growth control, cancer, and heritable disorders". Cell. 103 (2): 295–309. doi:10.1016/S0092-8674(00)00121-5. PMID 11057902. S2CID 15482063.
9. Lichtman, Michael K.; Otero-Vinas, Marta; Falanga, Vincent (March 2016). "Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis". Wound Repair and Regeneration. 24 (2): 215–222. doi:10.1111/wrr.12398. ISSN 1524-475X. PMID 26704519. S2CID 4967954.
10. Online Mendelian Inheritance in Man (OMIM): 190180
11. Universal protein resource accession number P01137 at UniProt.
12. Online Mendelian Inheritance in Man (OMIM): 190220
13. Universal protein resource accession number P61812 at UniProt.
14. Online Mendelian Inheritance in Man (OMIM): 190230
15. Universal protein resource accession number P10600 at UniProt.
16. Roberts, Anita B.; Kim, Seong-Jin; Noma, Takafumi; Glick, Adam B.; Lafyatis, Robert; Lechleider, Robert; Jakowlew, Sonia B.; Geiser, Andrew; O'Reilly, Michael A.; Danielpour, David; Sporn, Michael B. (2007). "Multiple Forms of TGF-β: Distinct Promoters and Differential Expression". Ciba Foundation Symposium 157 - Clinical Applications of TGF-β. Novartis Foundation Symposia. Vol. 157. pp. 7–28. doi:10.1002/9780470514061.ch2. ISBN 978-0-470-51406-1. PMID 1906395.
17. Khalil N (December 1999). "TGF-beta: from latent to active". Microbes and Infection. 1 (15): 1255–63. doi:10.1016/S1286-4579(99)00259-2. PMID 10611753.
18. Herpin A, Lelong C, Favrel P (May 2004). "Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans". Developmental and Comparative Immunology. 28 (5): 461–85. doi:10.1016/j.dci.2003.09.007. PMID 15062644.
19. Daopin S, Piez KA, Ogawa Y, Davies DR (July 1992). "Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily". Science. 257 (5068): 369–73. Bibcode:1992Sci...257..369D. doi:10.1126/science.1631557. PMID 1631557.
20. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. (1985). "Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells". Nature. 316 (6030): 701–5. Bibcode:1985Natur.316..701D. doi:10.1038/316701a0. PMID 3861940. S2CID 4245501.
21. Rifkin DB (March 2005). "Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability". The Journal of Biological Chemistry. 280 (9): 7409–12. doi:10.1074/jbc.R400029200. PMID 15611103.
22. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R (May 1995). "Processing of transforming growth factor beta 1 precursor by human furin convertase". The Journal of Biological Chemistry. 270 (18): 10618–24. doi:10.1074/jbc.270.18.10618. PMID 7737999.
23. Annes JP, Munger JS, Rifkin DB (January 2003). "Making sense of latent TGFbeta activation". Journal of Cell Science. 116 (Pt 2): 217–24. doi:10.1242/jcs.00229. PMID 12482908.
24. Saharinen J, Hyytiäinen M, Taipale J, Keski-Oja J (June 1999). "Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action". Cytokine & Growth Factor Reviews. 10 (2): 99–117. doi:10.1016/S1359-6101(99)00010-6. PMID 10743502.
25. Sterner-Kock A, Thorey IS, Koli K, Wempe F, Otte J, Bangsow T, et al. (September 2002). "Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer". Genes & Development. 16 (17): 2264–73. doi:10.1101/gad.229102. PMC 186672. PMID 12208849.
26. Saharinen J, Keski-Oja J (August 2000). "Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta". Molecular Biology of the Cell. 11 (8): 2691–704. doi:10.1091/mbc.11.8.2691. PMC 14949. PMID 10930463.
27. ten Dijke P, Hill CS (May 2004). "New insights into TGF-beta-Smad signalling". Trends in Biochemical Sciences. 29 (5): 265–73. doi:10.1016/j.tibs.2004.03.008. PMID 15130563.
28. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993). "Tumor cell interactions with the extracellular matrix during invasion and metastasis". Annual Review of Cell Biology. 9: 541–73. doi:10.1146/annurev.cb.09.110193.002545. PMID 8280471.
29. Barcellos-Hoff MH, Dix TA (September 1996). "Redox-mediated activation of latent transforming growth factor-beta 1". Molecular Endocrinology. 10 (9): 1077–83. doi:10.1210/mend.10.9.8885242. PMID 8885242.
30. Wipff PJ, Hinz B (September 2008). "Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship". European Journal of Cell Biology. 87 (8–9): 601–15. doi:10.1016/j.ejcb.2008.01.012. PMID 18342983.
31. Yu Q, Stamenkovic I (January 2000). "Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis". Genes & Development. 14 (2): 163–76. doi:10.1101/gad.14.2.163. PMC 316345. PMID 10652271.
32. Taipale J, Miyazono K, Heldin CH, Keski-Oja J (January 1994). "Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein". The Journal of Cell Biology. 124 (1–2): 171–81. doi:10.1083/jcb.124.1.171. PMC 2119892. PMID 8294500.
33. Lyons RM, Keski-Oja J, Moses HL (May 1988). "Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium". The Journal of Cell Biology. 106 (5): 1659–65. doi:10.1083/jcb.106.5.1659. PMC 2115066. PMID 2967299.
34. Booth WJ, Berndt MC (July 1987). "Thrombospondin in clinical disease states". Seminars in Thrombosis and Hemostasis. 13 (3): 298–306. doi:10.1055/s-2007-1003505. PMID 3317840. S2CID 28212659.
35. Raugi GJ, Olerud JE, Gown AM (December 1987). "Thrombospondin in early human wound tissue". The Journal of Investigative Dermatology. 89 (6): 551–4. doi:10.1111/1523-1747.ep12461198. PMID 3680981.
36. Schultz-Cherry S, Murphy-Ullrich JE (August 1993). "Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism". The Journal of Cell Biology. 122 (4): 923–32. doi:10.1083/jcb.122.4.923. PMC 2119591. PMID 8349738.
37. Murphy-Ullrich JE, Poczatek M (2000). "Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology". Cytokine & Growth Factor Reviews. 11 (1–2): 59–69. doi:10.1016/S1359-6101(99)00029-5. PMID 10708953.
38. Huang XZ, Wu JF, Cass D, Erle DJ, Corry D, Young SG, et al. (May 1996). "Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin". The Journal of Cell Biology. 133 (4): 921–8. doi:10.1083/jcb.133.4.921. PMC 2120829. PMID 8666675.
39. Bader BL, Rayburn H, Crowley D, Hynes RO (November 1998). "Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins". Cell. 95 (4): 507–19. doi:10.1016/S0092-8674(00)81618-9. PMID 9827803. S2CID 13076974.
40. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. (October 1992). "Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease". Nature. 359 (6397): 693–9. Bibcode:1992Natur.359..693S. doi:10.1038/359693a0. PMC 3889166. PMID 1436033.
41. Munger JS, Harpel JG, Giancotti FG, Rifkin DB (September 1998). "Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1". Molecular Biology of the Cell. 9 (9): 2627–38. CiteSeerX 10.1.1.492.5809. doi:10.1091/mbc.9.9.2627. PMC 25536. PMID 9725916.
42. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. (February 1999). "The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis". Cell. 96 (3): 319–28. doi:10.1016/S0092-8674(00)80545-0. PMID 10025398.
43. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. (January 1993). "Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death". Proceedings of the National Academy of Sciences of the United States of America. 90 (2): 770–4. Bibcode:1993PNAS...90..770K. doi:10.1073/pnas.90.2.770. PMC 45747. PMID 8421714.
44. Taylor AW (January 2009). "Review of the activation of TGF-beta in immunity". Journal of Leukocyte Biology. 85 (1): 29–33. doi:10.1189/jlb.0708415. PMC 3188956. PMID 18818372.
45. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, et al. (April 2002). "The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1". The Journal of Cell Biology. 157 (3): 493–507. doi:10.1083/jcb.200109100. PMC 2173277. PMID 11970960.
46. Derynck R, Zhang Y, Feng XH (December 1998). "Smads: transcriptional activators of TGF-beta responses". Cell. 95 (6): 737–40. doi:10.1016/S0092-8674(00)81696-7. PMID 9865691. S2CID 17711163.
47. Derynck R, Zhang YE (October 2003). "Smad-dependent and Smad-independent pathways in TGF-beta family signalling". Nature. 425 (6958): 577–84. Bibcode:2003Natur.425..577D. doi:10.1038/nature02006. PMID 14534577. S2CID 4419607.
48. Letterio JJ (August 2005). "TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia". Oncogene. 24 (37): 5701–12. doi:10.1038/sj.onc.1208922. PMID 16123803.
49. Zhang YE (February 2017). "Non-Smad Signaling Pathways of the TGF-β Family". Cold Spring Harbor Perspectives in Biology. 9 (2): a022129. doi:10.1101/cshperspect.a022129. PMC 5287080. PMID 27864313.
50. Roskoski R (August 2012). "ERK1/2 MAP kinases: structure, function, and regulation". Pharmacological Research. 66 (2): 105–43. doi:10.1016/j.phrs.2012.04.005. PMID 22569528.
51. Chen IT, Hsu PH, Hsu WC, Chen NJ, Tseng PH (July 2015). "Polyubiquitination of Transforming Growth Factor β-activated Kinase 1 (TAK1) at Lysine 562 Residue Regulates TLR4-mediated JNK and p38 MAPK Activation". Scientific Reports. 5: 12300. Bibcode:2015NatSR...512300C. doi:10.1038/srep12300. PMC 4507259. PMID 26189595.
52. Yang X, Khosravi-Far R, Chang HY, Baltimore D (June 1997). "Daxx, a novel Fas-binding protein that activates JNK and apoptosis". Cell. 89 (7): 1067–76. doi:10.1016/S0092-8674(00)80294-9. PMC 2989411. PMID 9215629.
53. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA (August 2001). "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation". Nature Cell Biology. 3 (8): 708–14. doi:10.1038/35087019. PMID 11483955. S2CID 20435808.
54. Hofmann TG, Stollberg N, Schmitz ML, Will H (December 2003). "HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells". Cancer Research. 63 (23): 8271–7. PMID 14678985.
55. Yingling, Jonathan M.; McMillen, William T.; Yan, Lei; Huang, Huocong; Sawyer, J. Scott; Graff, Jeremy; Clawson, David K.; Britt, Karen S.; Anderson, Bryan D.; Beight, Douglas W.; Desaiah, Durisala; Lahn, Michael M.; Benhadji, Karim A.; Lallena, Maria J.; Holmgaard, Rikke B.; Xu, Xiaohong; Zhang, Faming; Manro, Jason R.; Iversen, Philip W.; Iyer, Chandrasekar V.; Brekken, Rolf A.; Kalos, Michael D.; Driscoll, Kyla E. (23 January 2018). "Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor". Oncotarget. 9 (6): 6659–6677. doi:10.18632/oncotarget.23795. PMC 5805504. PMID 29467918. This article incorporates text from this source, which is available under the CC BY 3.0 license.
56. Johnston, Chris J. C.; Smyth, Danielle J.; Kodali, Ravindra B.; White, Madeleine P. J.; Harcus, Yvonne; Filbey, Kara J.; Hewitson, James P.; Hinck, Cynthia S.; Ivens, Alasdair; Kemter, Andrea M.; Kildemoes, Anna O.; Le Bihan, Thierry; Soares, Dinesh C.; Anderton, Stephen M.; Brenn, Thomas; Wigmore, Stephen J.; Woodcock, Hannah V.; Chambers, Rachel C.; Hinck, Andrew P.; McSorley, Henry J.; Maizels, Rick M. (December 2017). "A structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces regulatory T cells". Nature Communications. 8 (1): 1741. Bibcode:2017NatCo...8.1741J. doi:10.1038/s41467-017-01886-6. PMC 5701006. PMID 29170498.
57. Smyth, Danielle J.; Harcus, Yvonne; White, Madeleine P.J.; Gregory, William F.; Nahler, Janina; Stephens, Ian; Toke-Bjolgerud, Edward; Hewitson, James P.; Ivens, Alasdair; McSorley, Henry J.; Maizels, Rick M. (April 2018). "TGF-β mimic proteins form an extended gene family in the murine parasite Heligmosomoides polygyrus". International Journal for Parasitology. 48 (5): 379–385. doi:10.1016/j.ijpara.2017.12.004. PMC 5904571. PMID 29510118.
58. Mukundan, Ananya; Byeon, Chang-Hyeock; Hinck, Cynthia S.; Smyth, Danielle J.; Maizels, Rick M.; Hinck, Andrew P. (2020-12-09). "Structure-based mapping of the TβRI and TβRII receptor binding sites of the parasitic TGF-β mimic, Hp-TGM". doi:10.1101/2020.12.08.416701. S2CID 229293860. {{cite journal}}: Cite journal requires |journal= (help)
59. Cook, Laura; Reid, Kyle T; Häkkinen, Elmeri; de Bie, Brett; Tanaka, Shigeru; Smyth, Danielle J; White, Madeleine PJ; Wong, May Q; Huang, Qing; Gillies, Jana K; Zeigler, Steven F; Maizels, Rick M; Levings, Megan K (2021-04-30). "Induction of stable human FOXP3⁺ Tregs by a parasite-derived TGF-β mimic". Immunology & Cell Biology. 99 (8): 833–847. doi:10.1111/imcb.12475. PMC 8453874. PMID 33929751.
60. Eisenstein EM, Williams CB (May 2009). "The T(reg)/Th17 cell balance: a new paradigm for autoimmunity". Pediatric Research. 65 (5 Pt 2): 26R–31R. doi:10.1203/PDR.0b013e31819e76c7. PMID 19218879. S2CID 1778541.
61. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, Yoshimoto T (August 2009). "TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23". Biochemical and Biophysical Research Communications. 386 (1): 105–10. doi:10.1016/j.bbrc.2009.05.140. PMID 19501566.
62. Li MO, Flavell RA (August 2008). "TGF-beta: a master of all T cell trades". Cell. 134 (3): 392–404. doi:10.1016/j.cell.2008.07.025. PMC 3677783. PMID 18692464.
63. O'Connor W, Zenewicz LA, Flavell RA (June 2010). "The dual nature of T(H)17 cells: shifting the focus to function". Nature Immunology. 11 (6): 471–6. doi:10.1038/ni.1882. PMID 20485275. S2CID 2980102.
64. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006-01-01). "Transforming growth factor-beta regulation of immune responses". Annual Review of Immunology. 24 (1): 99–146. doi:10.1146/annurev.immunol.24.021605.090737. PMID 16551245.
65. Roes J, Choi BK, Cazac BB (June 2003). "Redirection of B cell responsiveness by transforming growth factor beta receptor". Proceedings of the National Academy of Sciences of the United States of America. 100 (12): 7241–6. Bibcode:2003PNAS..100.7241R. doi:10.1073/pnas.0731875100. PMC 165860. PMID 12773615.
66. Patil S, Wildey GM, Brown TL, Choy L, Derynck R, Howe PH (December 2000). "Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta -induced growth inhibition and apoptosis". The Journal of Biological Chemistry. 275 (49): 38363–70. doi:10.1074/jbc.M004861200. PMID 10995749.
67. Arsura M, Wu M, Sonenshein GE (July 1996). "TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha". Immunity. 5 (1): 31–40. doi:10.1016/S1074-7613(00)80307-6. PMID 8758892.
68. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (September 2012). "TGF-β - an excellent servant but a bad master". Journal of Translational Medicine. 10 (1): 183. doi:10.1186/1479-5876-10-183. PMC 3494542. PMID 22943793.
69. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, et al. (January 2005). "Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity". The Journal of Clinical Investigation. 115 (1): 66–75. doi:10.1172/JCI19229. PMC 539188. PMID 15630445.
70. Wahl SM (February 2007). "Transforming growth factor-beta: innately bipolar". Current Opinion in Immunology. 19 (1): 55–62. doi:10.1016/j.coi.2006.11.008. PMID 17137775.
71. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. (April 2011). "Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis". Science. 332 (6026): 243–7. Bibcode:2011Sci...332..243W. doi:10.1126/science.1201475. PMC 3144160. PMID 21436399.
72. Hanahan D, Weinberg RA (January 2000). "The hallmarks of cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931. S2CID 1478778.
73. Blobe GC, Schiemann WP, Lodish HF (May 2000). "Role of transforming growth factor beta in human disease". The New England Journal of Medicine. 342 (18): 1350–8. doi:10.1056/NEJM200005043421807. PMID 10793168.
74. Hassan, Sobia; Shah, Hussain; Shawana, Summayya (2020). "Dysregulated epidermal growth factor and tumor growth factor-beta receptor signaling through GFAP-ACTA2 protein interaction in liver fibrosis". Pakistan Journal of Medical Sciences. 36 (4): 782–787. doi:10.12669/pjms.36.4.1845. PMC 7260937. PMID 32494274.
75. Vlahopoulos SA, Cen O, Hengen N, Agan J, Moschovi M, Critselis E, et al. (August 2015). "Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment". Cytokine & Growth Factor Reviews. 26 (4): 389–403. doi:10.1016/j.cytogfr.2015.06.001. PMC 4526340. PMID 26119834.
76. Ezzeddini R, Somi MH, Taghikhani M, Moaddab SY, Masnadi Shirazi K, Shirmohammadi M, Eftekharsadat AT, Sadighi Moghaddam B, Salek Farrokhi A (February 2021). "Association of Foxp3 rs3761548 polymorphism with cytokines concentration in gastric adenocarcinoma patients". Cytokine. 138: 155351. doi:10.1016/j.cyto.2020.155351. ISSN 1043-4666. PMID 33127257. S2CID 226218796.
77. Bonecini-Almeida, M. Glória; Ho, John L.; Boéchat, Neio; Huard, Richard C.; Chitale, Sadhana; Doo, Howard; Geng, Jiayuan; Rego, Lorena; Lazzarini, Luiz Claudio Oliveira; Kritski, Afrânio L.; Johnson, Warren D.; McCaffrey, Timothy A.; Silva, José R. Lapa e (May 2004). "Down-Modulation of Lung Immune Responses by Interleukin-10 and Transforming Growth Factor β (TGF-β) and Analysis of TGF-β Receptors I and II in Active Tuberculosis". Infection and Immunity. 72 (5): 2628–2634. doi:10.1128/IAI.72.5.2628-2634.2004. PMC 387880. PMID 15102771.
78. Rook, Graham A. W.; Lowrie, Douglas B.; Hernàndez-Pando, Rogelio (15 July 2007). "Immunotherapeutics for Tuberculosis in Experimental Animals: Is There a Common Pathway Activated by Effective Protocols?". The Journal of Infectious Diseases. 196 (2): 191–198. doi:10.1086/518937. PMID 17570105.
79. Warsinske, Hayley C.; Pienaar, Elsje; Linderman, Jennifer J.; Mattila, Joshua T.; Kirschner, Denise E. (20 December 2017). "Deletion of TGF-β1 Increases Bacterial Clearance by Cytotoxic T Cells in a Tuberculosis Granuloma Model". Frontiers in Immunology. 8: 1843. doi:10.3389/fimmu.2017.01843. PMC 5742530. PMID 29326718.
80. Gern, Benjamin H.; Adams, Kristin N.; Plumlee, Courtney R.; Stoltzfus, Caleb R.; Shehata, Laila; Moguche, Albanus O.; Busman-Sahay, Kathleen; Hansen, Scott G.; Axthelm, Michael K.; Picker, Louis J.; Estes, Jacob D.; Urdahl, Kevin B.; Gerner, Michael Y. (March 2021). "TGFβ restricts expansion, survival, and function of T cells within the tuberculous granuloma". Cell Host & Microbe. 29 (4): 594–606.e6. doi:10.1016/j.chom.2021.02.005. PMC 8624870. PMID 33711270. S2CID 232217715.
81. Jayaswal, Shilpi; Kamal, Md. Azhar; Dua, Raina; Gupta, Shashank; Majumdar, Tanmay; Das, Gobardhan; Kumar, Dhiraj; Rao, Kanury V. S. (15 April 2010). "Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium tuberculosis through an siRNA Screen". PLOS Pathogens. 6 (4): e1000839. doi:10.1371/journal.ppat.1000839. PMC 2855445. PMID 20419122. S2CID 1769658.
82. Rosas-Taraco, Adrian G.; Higgins, David M.; Sánchez-Campillo, Joaquín; Lee, Eric J.; Orme, Ian M.; González-Juarrero, Mercedes (January 2011). "Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice". Tuberculosis. 91 (1): 98–106. doi:10.1016/j.tube.2010.11.004. PMC 7238550. PMID 21195670.
83. Understanding Heart Disease: Research Explains Link Between Cholesterol and Heart Disease Archived 2007-11-12 at the Wayback Machine
84. Entrez Gene (2007). "TGFBR2 transforming growth factor, beta receptor II" (Entrez gene entry). Retrieved January 11, 2007.
85. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. (April 2006). "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome". Science. 312 (5770): 117–21. Bibcode:2006Sci...312..117H. doi:10.1126/science.1124287. PMC 1482474. PMID 16601194.
86. Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G, Booms P, De Paepe A, et al. (October 2006). "The molecular genetics of Marfan syndrome and related disorders". Journal of Medical Genetics. 43 (10): 769–87. doi:10.1136/jmg.2005.039669. PMC 2563177. PMID 16571647.
87. Selvaraj RK, Geiger TL (March 2008). "Mitigation of experimental allergic encephalomyelitis by TGF-β induced FOXP3⁺ regulatory T cells through the induction of anergy and infectious tolerance". Journal of Immunology. 180 (5): 2830–8. doi:10.4049/jimmunol.180.5.2830. PMID 18292504.
88. Dobolyi A, Vincze C, Pál G, Lovas G (July 2012). "The neuroprotective functions of transforming growth factor beta proteins". International Journal of Molecular Sciences. 13 (7): 8219–58. doi:10.3390/ijms13078219. PMC 3430231. PMID 22942700.
89. Nakahara J, Maeda M, Aiso S, Suzuki N (February 2012). "Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy". Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. doi:10.1007/s12016-011-8287-6. PMID 22189514. S2CID 21058811.
90. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N (November 2010). "A meta-analysis of cytokines in Alzheimer's disease". Biological Psychiatry. 68 (10): 930–41. doi:10.1016/j.biopsych.2010.06.012. PMID 20692646. S2CID 6544784.
91. Senatorov VV, Friedman, AR, Milikovsky DZ, Ofer J, Saar-Ashkenazy R, Charbash A, Jahan N, Chin G, Mihaly E, Lin JM, Ramsay HJ, Moghbel A, Preininger MK, Eddings CR, Harrison HV, Patel R, Shen Y, Ghanim H, Sheng H, Veksler R, Sudmant PH, Becker A, Hart B, Rogawski MA, Dillin A, Friedman A, and Kaufer D (December 2019). "Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction". Science Translational Medicine. 11 (521): eaaw8283. bioRxiv 10.1101/537431. doi:10.1126/scitranslmed.aaw8283. PMID 31801886.
92. Daniela Kaufer; Alon Friedman (May 2021). "Damage to a Protective Shield around the Brain May Lead to Alzheimer's and Other Diseases". Scientific American.
93. Maier P, Broszinski A, Heizmann U, Böhringer D, Reinhardau T (July 2007). "Active transforming growth factor-beta2 is increased in the aqueous humor of keratoconus patients". Molecular Vision. 13: 1198–202. PMID 17679942.
94. Engler C, Chakravarti S, Doyle J, Eberhart CG, Meng H, Stark WJ, et al. (May 2011). "Transforming growth factor-β signaling pathway activation in Keratoconus". American Journal of Ophthalmology. 151 (5): 752–759.e2. doi:10.1016/j.ajo.2010.11.008. PMC 3079764. PMID 21310385.
95. Oddy WH, Rosales F (February 2010). "A systematic review of the importance of milk TGF-beta on immunological outcomes in the infant and young child". Pediatric Allergy and Immunology. 21 (1 Pt 1): 47–59. doi:10.1111/j.1399-3038.2009.00913.x. PMID 19594862.
96. Galindo, Yadira (2018-12-26). "UC San Diego Researchers Identify How Skin Ages, Loses Fat and Immunity" (Press release). University of California San Diego.
97. Zhang LJ, Chen SX, Guerrero-Juarez CF, Li F, Tong Y, Liang Y, et al. (January 2019). "Age-Related Loss of Innate Immune Antimicrobial Function of Dermal Fat Is Mediated by Transforming Growth Factor Beta". Immunity. 50 (1): 121–136.e5. doi:10.1016/j.immuni.2018.11.003. PMC 7191997. PMID 30594464.

Further reading

• Moses HL, Roberts AB, Derynck R (July 2016). "The Discovery and Early Days of TGF-β: A Historical Perspective". Cold Spring Harbor Perspectives in Biology. 8 (7): a021865. doi:10.1101/cshperspect.a021865. PMC 4930926. PMID 27328871.

External links

• Description of the TGF beta producing genes at ncbi.nlm.nih.gov
• Diagram of the TGF beta signaling pathway at genome.ad.jp
• The TGF-beta system—Nature Reviews Molecular Cell Biology
• SMART:TGFB domain annotation—European Molecular Biology Laboratory Heidelberg
• TGF-beta at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Biochemists Solve Structure Of TGF-Beta And Its Receptor. 2008 – shows TGF-β3 dimer in TGFB-receptor
• Measurement of Human Latent TGF-β1
• TGF beta pathway diagram
• IntroPro Entry - IPR016319